A list of 11 high-impact drugs has been identified as notable for 2026, with some outlets suggesting they could transform patient care. The development and pricing of these drugs may be influenced by various factors, including research priorities and negotiations over prices. The specific details and implications of these drugs are still emerging, with some related reports focusing on industry trends and others on broader healthcare topics.